<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38047713</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Differential inhibition of intra- and inter-molecular protease cleavages by antiviral compounds.</ArticleTitle><Pagination><StartPage>e0092823</StartPage><MedlinePgn>e0092823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00928-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.00928-23</ELocationID><Abstract><AbstractText>Most protease-targeted antiviral development evaluates the ability of small molecules to inhibit the cleavage of artificial substrates. However, before they can cleave any other substrates, viral proteases need to cleave themselves out of the viral polyprotein in which they have been translated. This can occur either intra- or inter-molecularly. Whether this process occurs intra- or inter-molecularly has implications for the potential for precursors to accumulate and for the effectiveness of antiviral drugs. We argue that evaluating candidate antivirals for their ability to block these cleavages is vital to drug development because the buildup of uncleaved precursors can be inhibitory to the virus and potentially suppress the selection of drug-resistant variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-3284-4297</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkegaard</LastName><ForeName>Karla</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7628-3770</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI171399</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D000085242">Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000084762">Viral Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020815">Polyproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085242" MajorTopicYN="Y">Viral Proteases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000084762" MajorTopicYN="Y">Viral Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020815" MajorTopicYN="N">Polyproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">enterovirus D68</Keyword><Keyword MajorTopicYN="N">picornavirus</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">polyprotein</Keyword><Keyword MajorTopicYN="N">positive-stranded RNA virus</Keyword><Keyword MajorTopicYN="N">protease</Keyword><Keyword MajorTopicYN="N">viral genetics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>4</Day><Hour>9</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38047713</ArticleId><ArticleId IdType="pmc">PMC10734437</ArticleId><ArticleId IdType="doi">10.1128/jvi.00928-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Faye M, Kébé O, Diop B, Ndiaye Nd, Dosseh A, Sam A, Diallo A, Dia H, Diallo JP, Dia N, Kiori DE, Diop OM, Sall AA, Faye O. 2022. Importation and circulation of vaccine-derived poliovirus serotype 2, Senegal, 2020-2021. Emerg Infect Dis 28:2027–2034. doi:10.3201/eid2810.220847</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2810.220847</ArticleId><ArticleId IdType="pmc">PMC9514370</ArticleId><ArticleId IdType="pubmed">36148906</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi G. 2020. Africa declared free from wild polio - but vaccine-derived strains remain. Nature. doi:10.1038/d41586-020-02501-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02501-3</ArticleId><ArticleId IdType="pubmed">32860027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopalco PL. 2017. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect 145:413–419. doi:10.1017/S0950268816002569</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002569</ArticleId><ArticleId IdType="pmc">PMC9507676</ArticleId><ArticleId IdType="pubmed">27866483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming LC, Hussain Z, Yeoh SF, Koh D, Lee KS. 2020. Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication. Global Health 16:63. doi:10.1186/s12992-020-00594-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12992-020-00594-z</ArticleId><ArticleId IdType="pmc">PMC7364572</ArticleId><ArticleId IdType="pubmed">32677974</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P. 2009. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27:2649–2652. doi:10.1016/j.vaccine.2009.02.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.02.071</ArticleId><ArticleId IdType="pubmed">19428874</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ, Dharmapalan D. 2022. Lessons from vaccine-related poliovirus in Israel, UK and USA. Vaccines (Basel) 10:1969. doi:10.3390/vaccines10111969</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111969</ArticleId><ArticleId IdType="pmc">PMC9695509</ArticleId><ArticleId IdType="pubmed">36423064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, MacDonald NE, Smith JC, Cai K, Yu H, Li H, Lei C. 2014. Severe enterovirus type 71 nervous system infections in children in the Shanghai Region of China. Pediatr Infect Dis J 33:482–487. doi:10.1097/INF.0000000000000194</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000194</ArticleId><ArticleId IdType="pubmed">24732390</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh H-L, Mohammad SS, Britton PN, Kandula T, Lorentzos MS, Booy R, Jones CA, Rawlinson W, Ramachandran V, Rodriguez ML, Andrews PI, Dale RC, Farrar MA, Sampaio H. 2016. Clinical characteristics and functional motor outcomes of enterovirus 71 neurological disease in children. JAMA Neurol 73:300–307. doi:10.1001/jamaneurol.2015.4388</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4388</ArticleId><ArticleId IdType="pubmed">26785318</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva EE, Winkler MT, Pallansch MA. 1996. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg Infect Dis 2:231–233. doi:10.3201/eid0203.960312</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0203.960312</ArticleId><ArticleId IdType="pmc">PMC2626804</ArticleId><ArticleId IdType="pubmed">8903236</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Asturias EJ, Hixon AM, Van Leer-Buter C, Niesters HGM, Tyler KL, Abzug MJ, Dominguez SR. 2018. Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis 18:e239–e247. doi:10.1016/S1473-3099(18)30094-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30094-X</ArticleId><ArticleId IdType="pmc">PMC6778404</ArticleId><ArticleId IdType="pubmed">29482893</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfferich J, Knoester M, Van Leer-Buter CC, Neuteboom RF, Meiners LC, Niesters HG, Brouwer OF. 2019. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr 178:1305–1315. doi:10.1007/s00431-019-03435-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-019-03435-3</ArticleId><ArticleId IdType="pmc">PMC6694036</ArticleId><ArticleId IdType="pubmed">31338675</ArticleId></ArticleIdList></Reference><Reference><Citation>Christy A, Messacar K. 2019. Acute flaccid myelitis associated with enterovirus D68: a review. J Child Neurol 34:511–516. doi:10.1177/0883073819838376</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073819838376</ArticleId><ArticleId IdType="pubmed">31014167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowers JR, Valentine M, Harrison V, Fofanov VY, Gillece J, Delisle J, Patton B, Schupp J, Sheridan K, Lemmer D, et al. . 2019. Genomic analyses of acute flaccid myelitis cases among a cluster in Arizona provide further evidence of enterovirus D68 role. mBio 10:e02262–18. doi:10.1128/mBio.02262-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02262-18</ArticleId><ArticleId IdType="pmc">PMC6343034</ArticleId><ArticleId IdType="pubmed">30670612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizcano-Perret B, Michiels T. 2021. Nucleocytoplasmic trafficking perturbation induced by picornaviruses. Viruses 13:1210. doi:10.3390/v13071210</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071210</ArticleId><ArticleId IdType="pmc">PMC8310216</ArticleId><ArticleId IdType="pubmed">34201715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Hilgenfeld R. 2017. RNA‐virus proteases counteracting host innate immunity. FEBS Lett 591:3190–3210. doi:10.1002/1873-3468.12827</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12827</ArticleId><ArticleId IdType="pmc">PMC7163997</ArticleId><ArticleId IdType="pubmed">28850669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsu BV, Fay EJ, Nguyen KT, Corley MR, Hosuru B, Dominguez VA, Daugherty MD. 2021. Running with scissors: evolutionary conflicts between viral proteases and the host immune system. Front Immunol 12:769543. doi:10.3389/fimmu.2021.769543</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.769543</ArticleId><ArticleId IdType="pmc">PMC8591160</ArticleId><ArticleId IdType="pubmed">34790204</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A, Álvarez E, Carrasco L. 2011. The multifaceted poliovirus 2A protease: regulation of gene expression by picornavirus proteases. J Biomed Biotechnol 2011:369648. doi:10.1155/2011/369648</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/369648</ArticleId><ArticleId IdType="pmc">PMC3085340</ArticleId><ArticleId IdType="pubmed">21541224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventoso I, MacMillan SE, Hershey JW b, Carrasco L. 1998. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 435:79–83. doi:10.1016/s0014-5793(98)01027-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(98)01027-8</ArticleId><ArticleId IdType="pubmed">9755863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bera AK, Kuhn RJ, Smith JL. 2007. Functional characterization of cis and trans activity of the flavivirus NS2B-NS3 protease. J Biol Chem 282:12883–12892. doi:10.1074/jbc.M611318200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611318200</ArticleId><ArticleId IdType="pubmed">17337448</ArticleId></ArticleIdList></Reference><Reference><Citation>Constant DA, Mateo R, Nagamine CM, Kirkegaard K. 2018. Targeting intramolecular proteinase NS2B/3 cleavages for trans-dominant inhibition of dengue virus. Proc Natl Acad Sci USA 115:10136–10141. doi:10.1073/pnas.1805195115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1805195115</ArticleId><ArticleId IdType="pmc">PMC6176606</ArticleId><ArticleId IdType="pubmed">30228122</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasiljeva L, Merits A, Golubtsov A, Sizemskaja V, Kääriäinen L, Ahola T. 2003. Regulation of the sequential processing of semliki forest virus replicase polyprotein. J Biol Chem 278:41636–41645. doi:10.1074/jbc.M307481200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M307481200</ArticleId><ArticleId IdType="pubmed">12917405</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot RJ, Hardy WR, Shirako Y, Strauss JH. 1990. Cleavage-site preferences of Sindbis virus polyproteins containing the non-structural proteinase. evidence for temporal regulation of polyprotein processing in vivo. EMBO J 9:2631–2638. doi:10.1002/j.1460-2075.1990.tb07445.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1990.tb07445.x</ArticleId><ArticleId IdType="pmc">PMC552296</ArticleId><ArticleId IdType="pubmed">2142454</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Perales C. 2018. Quasispecies and virus. Eur Biophys J 47:443–457. doi:10.1007/s00249-018-1282-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00249-018-1282-6</ArticleId><ArticleId IdType="pubmed">29397419</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda H, Nicklin MJH, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761–770. doi:10.1016/0092-8674(86)90790-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(86)90790-7</ArticleId><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellen CU, Lee CK, Wimmer E. 1992. Determinants of substrate recognition by poliovirus 2A proteinase. J Virol 66:3330–3338. doi:10.1128/JVI.66.6.3330-3338.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.66.6.3330-3338.1992</ArticleId><ArticleId IdType="pmc">PMC241111</ArticleId><ArticleId IdType="pubmed">1316450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicklin MJH, Kräusslich HG, Toyoda H, Dunn JJ, Wimmer E. 1987. Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases. Proc Natl Acad Sci USA 84:4002–4006. doi:10.1073/pnas.84.12.4002</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.84.12.4002</ArticleId><ArticleId IdType="pmc">PMC305009</ArticleId><ArticleId IdType="pubmed">3035560</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvey JC, Wyckoff EE, Yu SF, Lloyd R, Ehrenfeld E. 1991. Cis- and trans-cleavage activities of poliovirus 2A protease expressed in Escherichia coli. J Virol 65:6077–6083. doi:10.1128/JVI.65.11.6077-6083.1991</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.65.11.6077-6083.1991</ArticleId><ArticleId IdType="pmc">PMC250281</ArticleId><ArticleId IdType="pubmed">1656087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma-Wong MF, Dewalt PG, Johnson VH, Lamb JG, Semler BL. 1988. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology 166:265–270. doi:10.1016/0042-6822(88)90172-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(88)90172-9</ArticleId><ArticleId IdType="pubmed">2842953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jore J, De Geus B, Jackson RJ, Pouwels PH, Enger-Valk BE. 1988. Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J Gen Virol 69:1627–1636. doi:10.1099/0022-1317-69-7-1627</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-69-7-1627</ArticleId><ArticleId IdType="pubmed">2839599</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson MA, Semler BL. 1992. Alternate poliovirus nonstructural protein processing cascades generated by primary sites of 3C proteinase cleavage. Virology 191:309–320. doi:10.1016/0042-6822(92)90193-s</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(92)90193-s</ArticleId><ArticleId IdType="pubmed">1329322</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcotte LL, Wass AB, Gohara DW, Pathak HB, Arnold JJ, Filman DJ, Cameron CE, Hogle JM. 2007. Crystal structure of poliovirus 3CD protein: virally encoded protease and precursor to the RNA-dependent RNA polymerase. J Virol 81:3583–3596. doi:10.1128/JVI.02306-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02306-06</ArticleId><ArticleId IdType="pmc">PMC1866080</ArticleId><ArticleId IdType="pubmed">17251299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma-Wong MF, Semler BL. 1987. In vitro molecular genetics as a tool for determining the differential cleavage specificities of the poliovirus 3C proteinase. Nucleic Acids Res 15:2069–2088. doi:10.1093/nar/15.5.2069</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/15.5.2069</ArticleId><ArticleId IdType="pmc">PMC340618</ArticleId><ArticleId IdType="pubmed">3031587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanecak R, Semler BL, Ariga H, Anderson CW, Wimmer E. 1984. Expression of a cloned gene segment of poliovirus in E. coli: evidence for autocatalytic production of the viral proteinase. Cell 37:1063–1073. doi:10.1016/0092-8674(84)90441-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(84)90441-0</ArticleId><ArticleId IdType="pubmed">6331675</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmenberg AC, Rueckert RR. 1982. Evidence for intramolecular self-cleavage of picornaviral replicase precursors. J Virol 41:244–249. doi:10.1128/JVI.41.1.244-249.1982</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.41.1.244-249.1982</ArticleId><ArticleId IdType="pmc">PMC256745</ArticleId><ArticleId IdType="pubmed">6283117</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmenberg AC. 1990. Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol 44:603–623. doi:10.1146/annurev.mi.44.100190.003131</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003131</ArticleId><ArticleId IdType="pubmed">2252396</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks GD, Baker JC, Palmenberg AC. 1989. Proteolytic cleavage of encephalomyocarditis virus capsid region substrates by precursors to the 3C enzyme. J Virol 63:1054–1058. doi:10.1128/JVI.63.3.1054-1058.1989</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.63.3.1054-1058.1989</ArticleId><ArticleId IdType="pmc">PMC247798</ArticleId><ArticleId IdType="pubmed">2536819</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak HB, Oh HS, Goodfellow IG, Arnold JJ, Cameron CE. 2008. Picornavirus genome replication. J Biol Chem 283:30677–30688. doi:10.1074/jbc.M806101200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M806101200</ArticleId><ArticleId IdType="pmc">PMC2576561</ArticleId><ArticleId IdType="pubmed">18779320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorner AJ, Semler BL, Jackson RJ, Hanecak R, Duprey E, Wimmer E. 1984. In vitro translation of poliovirus RNA: utilization of internal initiation sites in reticulocyte lysate. J Virol 50:507–514. doi:10.1128/JVI.50.2.507-514.1984</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.50.2.507-514.1984</ArticleId><ArticleId IdType="pmc">PMC255658</ArticleId><ArticleId IdType="pubmed">6323749</ArticleId></ArticleIdList></Reference><Reference><Citation>Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong Y-P, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50:899–909. doi:10.1128/AAC.50.3.899-909.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.50.3.899-909.2006</ArticleId><ArticleId IdType="pmc">PMC1426435</ArticleId><ArticleId IdType="pubmed">16495249</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, Wang J. 2019. Validating enterovirus D68-2Apro as an antiviral drug target and the discovery of telaprevir as a potent D68-2Apro inhibitor. J Virol 93:e02221–18. doi:10.1128/JVI.02221-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02221-18</ArticleId><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Deszcz L, Cencic R, Sousa C, Kuechler E, Skern T. 2006. An antiviral peptide inhibitor that is active against picornavirus 2A proteinases but not cellular caspases. J Virol 80:9619–9627. doi:10.1128/JVI.00612-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00612-06</ArticleId><ArticleId IdType="pmc">PMC1617246</ArticleId><ArticleId IdType="pubmed">16973565</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43:2444–2450. doi:10.1128/AAC.43.10.2444</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.10.2444</ArticleId><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, Matthews DA, Patick AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619–626. doi:10.1128/AAC.49.2.619-626.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJM, Leyssen P, Hilgenfeld R, Neyts J, Delang L. 2015. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob Agents Chemother 59:7782–7785. doi:10.1128/AAC.01375-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanko K, Shi C, Patil S, Delang L, Matthijnssens J, Mirabelli C, Neyts J. 2020. Assessing in vitro resistance development in enterovirus A71 in the context of combination antiviral treatment. ACS Infect Dis 7:2801–2806. doi:10.1021/acsinfecdis.0c00872</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00872</ArticleId><ArticleId IdType="pubmed">34529400</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Pereira J, Nascimento MSJ, Ma Q, Hilgenfeld R, Neyts J, Jochmans D. 2014. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob Agents Chemother 58:4675–4681. doi:10.1128/AAC.02546-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02546-13</ArticleId><ArticleId IdType="pmc">PMC4136040</ArticleId><ArticleId IdType="pubmed">24890597</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J. 2008. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 14:545–551. doi:10.3201/eid1404.070439</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1404.070439</ArticleId><ArticleId IdType="pmc">PMC2570929</ArticleId><ArticleId IdType="pubmed">18394270</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Caglar MU, Mao Z, Woodman A, Arnold JJ, Wilke CO, Cameron CE. 2019. More than efficacy revealed by single-cell analysis of antiviral therapeutics. Sci Adv 5:1–8. doi:10.1126/sciadv.aax4761</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aax4761</ArticleId><ArticleId IdType="pmc">PMC6821460</ArticleId><ArticleId IdType="pubmed">31692968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard K, van Buuren NJ, Mateo R. 2016. My cousin, my enemy: quasispecies suppression of drug resistance. Curr Opin Virol 20:106–111. doi:10.1016/j.coviro.2016.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.09.011</ArticleId><ArticleId IdType="pmc">PMC5298929</ArticleId><ArticleId IdType="pubmed">27764731</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowder S, Kirkegaard K. 2005. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nat Genet 37:701–709. doi:10.1038/ng1583</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1583</ArticleId><ArticleId IdType="pubmed">15965477</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Lidsky PV, Shirogane Y, Aviner R, Wu CT, Li W, Zheng W, Talbot D, Catching A, Doitsh G, Su W, Gekko CE, Nayak A, Ernst JD, Brodsky L, Brodsky E, Rousseau E, Capponi S, Bianco S, Nakamura R, Jackson PK, Frydman J, Andino R. 2021. A defective viral genome strategy elicits broad protective immunity against respiratory viruses. Cell 184:6037–6051. e14. doi:10.1016/j.cell.2021.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.023</ArticleId><ArticleId IdType="pmc">PMC8598942</ArticleId><ArticleId IdType="pubmed">34852237</ArticleId></ArticleIdList></Reference><Reference><Citation>Yost SA, Marcotrigiano J. 2013. Viral precursor polyproteins: keys of regulation from replication to maturation. Curr Opin Virol 3:137–142. doi:10.1016/j.coviro.2013.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.03.009</ArticleId><ArticleId IdType="pmc">PMC3660988</ArticleId><ArticleId IdType="pubmed">23602469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner T, Müller A, Pankraz A, Becher P, Thiel H-J, Gorbalenya AE, Tautz N. 2004. Temporal modulation of an autoprotease is crucial for replication and pathogenicity of an RNA virus. J Virol 78:10765–10775. doi:10.1128/JVI.78.19.10765-10775.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.19.10765-10775.2004</ArticleId><ArticleId IdType="pmc">PMC516412</ArticleId><ArticleId IdType="pubmed">15367643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemm JA, Rice CM. 1993. Assembly of functional Sindbis virus RNA replication complexes: requirement for coexpression of P123 and P34. J Virol 67:1905–1915. doi:10.1128/JVI.67.4.1905-1915.1993</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.67.4.1905-1915.1993</ArticleId><ArticleId IdType="pmc">PMC240258</ArticleId><ArticleId IdType="pubmed">8445716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemm JA, Rümenapf T, Strauss EG, Strauss JH, Rice CM. 1994. Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J 13:2925–2934. doi:10.1002/j.1460-2075.1994.tb06587.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1994.tb06587.x</ArticleId><ArticleId IdType="pmc">PMC395174</ArticleId><ArticleId IdType="pubmed">7517863</ArticleId></ArticleIdList></Reference><Reference><Citation>Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. 1993. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA 90:10583–10587. doi:10.1073/pnas.90.22.10583</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.22.10583</ArticleId><ArticleId IdType="pmc">PMC47821</ArticleId><ArticleId IdType="pubmed">8248148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed KE, Grakoui A, Rice CM. 1995. Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage. J Virol 69:4127–4136. doi:10.1128/JVI.69.7.4127-4136.1995</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.7.4127-4136.1995</ArticleId><ArticleId IdType="pmc">PMC189148</ArticleId><ArticleId IdType="pubmed">7769671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 68:5045–5055. doi:10.1128/JVI.68.8.5045-5055.1994</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.68.8.5045-5055.1994</ArticleId><ArticleId IdType="pmc">PMC236447</ArticleId><ArticleId IdType="pubmed">8035505</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommergruber W, Zorn M, Blaas D, Fessl F, Volkmann P, Maurer-Fogy I, Pallai P, Merluzzi V, Matteo M, Skern T, Kuechler E. 1989. Polypeptide 2A of human rhinovirus type 2: identification as a protease and characterization by mutational analysis. Virology 169:68–77. doi:10.1016/0042-6822(89)90042-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(89)90042-1</ArticleId><ArticleId IdType="pubmed">2538037</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R, Vignuzzi M, Andino R, Frydman J. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 21:195–205. doi:10.1101/gad.1505307</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1505307</ArticleId><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Cheng A, Wang M, Jia R, Sun K, Pan K, Yang Q, Wu Y, Zhu D, Chen S, Liu M, Zhao X-X, Chen X. 2017. Structures and corresponding functions of five types of picornaviral 2A proteins. Front Microbiol 8:1373. doi:10.3389/fmicb.2017.01373</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01373</ArticleId><ArticleId IdType="pmc">PMC5519566</ArticleId><ArticleId IdType="pubmed">28785248</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly MLL, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD. 2001. Analysis of the aphthovirus 2A/2B polyprotein “cleavage” mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal “skip”. J Gen Virol 82:1013–1025. doi:10.1099/0022-1317-82-5-1013</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-82-5-1013</ArticleId><ArticleId IdType="pubmed">11297676</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrill CP, Strings VR, Schulte MB, Andino R. 2013. Poliovirus: generation and characterization of mutants. Curr Protoc Microbiol Chapter 15:15H.2.1-15H.2.32. doi:10.1002/9780471729259.mc15h02s29</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780471729259.mc15h02s29</ArticleId><ArticleId IdType="pmc">PMC4826568</ArticleId><ArticleId IdType="pubmed">23686829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard K. 1990. Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA. J Virol 64:195–206. doi:10.1128/JVI.64.1.195-206.1990</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.64.1.195-206.1990</ArticleId><ArticleId IdType="pmc">PMC249083</ArticleId><ArticleId IdType="pubmed">2152812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>